Pharmacological protection of the ischemic myocardium by derivatives of 3-(2,2,2-trimethylhydrazinium) propionate and evaluation of their antioxidant activity

Авторы

  • S.Ya. Skachilova JSC "All-Russian scientific centre BAS"
  • L.M. Danilenko Belgorod State National Research University
  • O.G. Kesarev JSC "All-Russian scientific centre BAS"
  • I.S. Kochkarova Belgorod State National Research University

DOI:

https://doi.org/10.18413/2500-235X-2015-1-4-25-31

Аннотация

The paper presents results of a study of antioxidant (in vitro) and anti-ischemic effect of a number derivatives of 3-(2,2,2-trimethylhydrazinium) propionate. It was revealed that among other compounds 5-hydroxynicotinate of 3-(2,2,2-trimethylhydrazinium) propionate had the most pronounced antioxidant activity. The effect of 3-(2,2,2-trimethylhydrazinium) propionate and its derivatives on the necrotized area of the myocardium of the left ventricle in the course of simulation of myocardial infarction with coronary occlusion in rabbits showed that pharmacological preconditioning by 3-(2,2,2-trimethylhydrazinium) propionate and its derivatives could be considered as prevention of a syndrome of ischemia/reperfusion injury in case of myocardial infarction. Thus it was demonstrated that both 3-(2,2,2-trimethylhydrazinium) propionate (40 mg/kg) and its derivatives, namely nicotinate (84.1 mg/kg), 5-bromonicotinate (105.5 mg/kg), 5-hydroxynicotinate (88.5 mg/kg) and glycine (71.0 mg/kg) had anti-ischemic activity expressed in effective decrease of the area of necrotized infarction and reduction of the level of Tn I in the blood plasma as compared to the reference substance, i.e. Mildronate®.

Ключевые слова:

3-(2,2,2-trimethylhydrazinium) propionate, ischemia/reperfusion, antioxidant activity, preconditioning

Библиографические ссылки

G. A. Akimov, V. Yu Polumiskova. Prospects of application of myocardial cytoprotectors in cardiology practice [Electronic resource]. Terra medica. Cardiology. No. 4. (2005): P 21-23. URL: http://www.terramedica.spb.ru/4_2005/akimov.htm.

L. M. Danilenko, O. V. Kharitonova, M. V. Pokrovsky. Endotheliazation Mildronate and its derivatives in modeling L-NAME induced nitrogen oxide. Scientific statement BSU. Ser. Medicine. Pharmacy. № 16, vol. 22/2 (2011): P. 58-62.

L. M. Danilenko, M. V. Pokrovsky O. V. Kharitonova Effects of inducible, endothelial NO synthase ATP-dependent potassium channels in effects of 3-(2,2,2-trimethylhydrazine) propionate and distant preconditioning in the simulation koronarolitikov myocardial infarction. Bulletin of the Volgograd state medical University. Proceedings of the III all-Russian. scientific.-practical. seminar for mol. scientists "Methodol. aspects of experimental. and the clinical. pharmacology", Volgograd, 20-21 Sept. (2011): P. 24-25.

M. V. Korokhin, E. N. Pashin, V. M. Pokrovskii. Study endotelialnogo and coronary action of derivatives of 3-oksipiridina/ // Kuban Scientific medical Bulletin. №4 (2009): P. 104-108.

Lukyanova L. D. New approaches to the creation of antihypoxants of metabolic action. Bulletin of the Russian Academy of medical Sciences. №3 (1999): P. 18-25.

E. B. Manukhina, I. Y. Malyshev, D. A. Pokidishev. Role of free and deposited of nitric oxide in adaptation to hypoxia cardiovascular system. Regional circulation and microcirculation. №3 (2004): Р. 3-11.

Hjalmarson. Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter?. Basic Res Cardiol. Vol. 95 (2000): P. L41-L45.

Sesti, B.Z. Simkhovich, I. Kalvinsh. Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting hemodynamics. J. Cardiovasc. Pharmacol. № 3. Vol. 47 (2006): P. 493-499.

R.S. Schofield., J.A. Hill Schofield. Role of metabolically active drugs in the management of ischemic heart disease. Am. J. Cardiovasc. Drugs. Vol. 1, № 1. (2001): P. 23-35.

N. Sjakste, A.L. Kleschyov, J.L. Boucher. Endothelium- and nitric oxide-dependent vasorelaxing activities of gamma-butyrobetaine esters: possible link to the antiischemic activities of mildronate. Eur. J. Pharmacol. Vol. 495, № 1 (2004). P. 67-73.

Вклад авторов

S.Ya. Skachilova, JSC "All-Russian scientific centre BAS"

Doctor of Science (Chemistry), head of department in the laboratory of chemistry and technology of synthetic drugs

L.M. Danilenko, Belgorod State National Research University

Candidate of Science (Pharmaceutics), Associate Professor of the Department of Pharmacology of the Medical Institute

O.G. Kesarev, JSC "All-Russian scientific centre BAS"

Candidate of Science (Chemistry), head of the substances synthesis technology sector

I.S. Kochkarova, Belgorod State National Research University

Researcher at the Center of preclinical and clinical studies

Загрузки

Опубликован

30.12.2015

Как цитировать

Skachilova S, Danilenko L, Kesarev O, Kochkarova I (2015) Pharmacological protection of the ischemic myocardium by derivatives of 3-(2,2,2-trimethylhydrazinium) propionate and evaluation of their antioxidant activity. Research Results in Pharmacology 1(1): 23–27. https://doi.org/10.18413/2500-235X-2015-1-4-25-31

Выпуск

Раздел

Экспериментальная фармакология